Soliton Inc

We’re excited to announce that Allergan Aesthetics, an AbbVie company has acquired Soliton to complement their body-contouring portfolio. We are honored to join the brand's legacy of cutting-edge innovation and look forward to further growing our impact together.

Allergan Aesthetics Completes Acquisition of Soliton /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ:...

— Soliton's RESONIC™ FEATURED in Harper's Bazaar

Katie Intner, Beauty Editor at Harper's Bazaar wrote “For those who wish to diminish the appearance of cellulite, most dermatological treatments have failed to deliver sustainable or even dramatically noticeable results. A new technology, called RESONIC, aims to change all that.”

Read the full article here: https://bit.ly/3bl00Gk.

— Soliton Reports First Quarter 2021 Results

Read the full details here: https://bit.ly/3tIGWYQ.

Soliton Reports First Quarter 2021 Results Soliton Reports First Quarter 2021 Results Download as PDF May 12, 2021 Related Documents Audio Earnings Webcast HOUSTON, May 12, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today reported...

Another reason why RESONIC™ is a game-changer.

Tattoo removal has been reimagined. A new breakthrough is coming, using Rapid Acoustic Pulse™ technology that works with laser therapy for:


• Fewer sessions
• Faster results
• Unparalleled effectiveness when compared to laser tattoo removal treatments alone

Learn more here: http://www.resonic.com/

— Introducing RESONIC™

Soliton, Inc. Rolls Out Its Rapid Acoustic Pulse™ Technology with a Multi-Platform Device Indicated for Tattoo Removal and Cellulite Treatment with First Shipments in June

Using Rapid Acoustic Pulse™ technology, Soliton’s RESONIC device provides a first-of-its-kind treatment that will change the way cellulite is treated by physically changing the bands beneath the skin that cause cellulite to reveal smoother skin with as little as one treatment.

RESONIC clears cellular barriers, making the laser removal technology more effective so patients can be set free from their tattoos in as few as three sessions.

Read about the details for the next wave of tattoo removal and cellulite treatment here: https://bit.ly/3tfSi6F

— Soliton to Report First Quarter 2021 Financial Results on May 13, 2021

Please tune in to our conference call and webcast on Thursday, May 13 at 4:30 p.m. ET to discuss the results.

For participation details, view the full announcement here: https://bit.ly/33c0SbI.

$SOLY

Soliton to Report First Quarter 2021 Financial Results on May 13, 2021 Soliton to Report First Quarter 2021 Financial Results on May 13, 2021 Download as PDF May 04, 2021 Conference Call to Discuss Results on May 13, 2021 at 4:30 p.m. ET HOUSTON, May 4, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a nove...

Nicki Hawkins is a well-seasoned digital marketer with extensive experience in the social and digital media universe. With her deep expertise in digital communications and content strategy, Nicki will be responsible for developing online marketing strategies and techniques to establish RESONIC’s digital footprint.

— Soliton Receives FDA Clearance of Special 510(k)

Brad Hauser, President and CEO of Soliton commented, "We were thrilled to receive this clearance as it marks the last significant hurdle to our ability to initiate our commercial launch of the improved RESONIC device in the second quarter. Our discussions with our target dermatologists and plastic surgeons on our Rapid Acoustic Pulse (RAP) technology have been very well received and there is strong enthusiasm for an effective and efficient patient experience for tattoo removal and cellulite treatment with the RESONIC device over the coming months."

Read more about how this notification paves way for our planned second quarter commercial launch: https://bit.ly/3nB8XjF.

Soliton Receives FDA Clearance of Special 510(k) Soliton Receives FDA Clearance of Special 510(k) Download as PDF April 29, 2021 Notification paves way for second quarter commercial launch HOUSTON, April 29, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platfo...

— Dr. Elizabeth Tanzi, Founder and Director of Capital Laser & Skin Care and a member of Soliton's Scientific Advisory Board, spoke with Modern Aesthetics about our technology's role in the short-term improvement of cellulite. Access this link for the full piece: https://bit.ly/2RK7ps1.

— Soliton Provides Special 510(k) and Commercialization Update

Brad Hauser, President and CEO of the Company, commented, "With the FDA's acceptance of our special 510(k) application for improved commercial use and successful completion of all safety testing, we believe are well-positioned to successfully bring RESONIC™ to market later this quarter."

Read the full details here: https://bit.ly/2ORBOn5.

Soliton Provides Special 510(k) and Commercialization Update Soliton Provides Special 510(k) and Commercialization Update Download as PDF April 15, 2021 HOUSTON, April 15, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the U.S. Foo...

— We all can imagine the toll cancer takes on individuals and their families. Mary Stoll, our Senior Director for Clinical Development shares how she helps the fight against cancer with the Dana-Farber Cancer Institute.